N
NYMOX SEREX
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.
Country/Area ：United States
Company Email ：info@nymox.com
Industry ：ElectronicsHealthcareDrug Manufacturing & ResearchPharmaceuticals
Company address ：Bay & Deveaux Sts, Nassau, New Providence, Bahamas
Company website ：*****
Company phone ：(800) 936-9669
Established ：1989
Company Revenue ：$635,000
Number of employees ：<25
SIC Code ：28283
NAICS Code ：54541
Main Products ：Fexapotide for BPHStock InfoNicAlert ®Recent scientific publications featuring Fexapotide TriflutateSEC FilingsFor the treatment of Benign Prostate Hyperplasia (BPH)Research strategyNymox Annual ReportAnnual ReportsFexapotide TriflutateTobacAlert ®Scientific PublicationsOngoing research for Fexapotide in BPH and low-grade localized prostate cancer
Company News
The Committee to Restore Nymox Shareholder Value Sends Letter to Nymox Pharmaceutical Shareholders and Issues Proxy Materials for Upcoming Special Meeting
Oct 23, 2023
CARSON CITY, Nev. & LONDON--(BUSINESS WIRE)--THE COMMITTEE TO RESTORE NYMOX SHAREHOLDER VALUE SENDS LETTER TO NYMOX PHARMACEUTICAL SHAREHOLDERS
Oct 23, 2023
The Committee to Restore Nymox Shareholder Value Issues Notice of Special Meeting of Nymox Pharmaceutical ShareholdersOct 11, 2023
CARSON CITY, Nev. & LONDON--(BUSINESS WIRE)--The Committee to Restore Nymox Shareholder Value, Inc. (CRNSV), with a goal to recover shareholder value in Nymox Pharmaceutical Corporation (NYMX-F) (the “Company” or “Nymox”), today announced that pursuant to the October 5, 2023 Order of Court in Bahamas Supreme Court (the “Court”) Action No. 2023/Com/com/00057 (the “Order”), it has issued notice of the special meeting of Nymox shareholders (the “Notice”) to be held at Margaritaville Beach Resort,
Oct 11, 2023Nymox responds as the Bahamas Supreme Court Rules in Favor of the Committee to Restore Nymox Shareholder Value: Grants Injunction Order Freezing CEO Averback Shares and Orders Shareholder Meeting.Oct 10, 2023
CARSON CITY, Nev. & LONDON--(BUSINESS WIRE)--Nymox responds as the Bahamas Supreme Court Rules in Favor of the Committee to Restore Nymox Shareholder Value
Oct 10, 2023Bahamas Supreme Court Rules in Favor of Committee to Restore Nymox Shareholder Value: Orders Shareholder Meeting, Grants Injunction Freezing CEO SharesOct 6, 2023
CARSON CITY, Nev. & LONDON--(BUSINESS WIRE)--Bahamas Supreme Court Rules in Favor of CRNSV: Orders Shareholder Meeting, Grants Injunction Freezing CEO Shares
Oct 6, 2023Surge of Shareholders Joins The Committee to Restore Nymox Shareholder Value, Deluge Website with Emails Expressing Dissatisfaction with NYMOX LeadershipAug 8, 2023
CARSON CITY, Nev. & LONDON--(BUSINESS WIRE)--Surge of Shareholders Joins Committee to Restore Nymox Shareholder Value, Deluge Website with Emails Expressing Dissatisfaction with NYMOX Leadership
Aug 8, 2023Web Summary
Q1: What is the address of Nymox Pharmaceutical Corporation's principal executive offices?
A1: The principal executive offices of Nymox Pharmaceutical Corporation are located at 4 Park Plaza, Irvine, CA 92614.
Q2: What products does Nymox Pharmaceutical Corporation offer?
A2: Nymox Pharmaceutical Corporation offers two diagnostic products, NicAlert and TobacAlert, as well as a lead drug candidate for benign prostatic hyperplasia (BPH) called Fexapotide Triflutate (FT).
Q3: In which industry is Nymox Pharmaceutical Corporation primarily involved?
A3: Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies.
Q4: What is the company's focus regarding its lead drug candidate Fexapotide Triflutate (FT)?
A4: The Company's lead drug candidate FT has completed Phase 3 development in more than 70 clinical centers in the United States, involving over 1700 patients during the entire clinical development program. It is also being developed for early-stage, non-aggressive prostate cancer.
Q5: What is the significance of Fexapotide Triflutate (FT) in treating benign prostatic hyperplasia (BPH)?
A5: FT has demonstrated important long-term clinical benefits in men receiving FT, including significant delay in disease progression compared to controls. It offers long-term symptom relief in BPH in excess of currently available oral medications and with no side-effects.
Q6: Where is Nymox Pharmaceutical Corporation headquartered?
A6: The Company is headquartered in Nassau, Bahamas, but it is currently relocating its headquarters from the Bahamas to Switzerland.
Q7: What is the company's stock symbol on NASDAQ National Market?
A7: Nymox Pharmaceutical Corporation's stock is traded on NASDAQ National Market under the symbol NYMX.
Q8: Who is the founder, CEO, and President of Nymox Pharmaceutical Corporation?
A8: Dr. Paul Averback is the founder, CEO, and President of Nymox Pharmaceutical Corporation. He has extensive experience in healthcare and holds a Diploma of the American Board of Pathology with special competence in Neuropathology.
A1: The principal executive offices of Nymox Pharmaceutical Corporation are located at 4 Park Plaza, Irvine, CA 92614.
Q2: What products does Nymox Pharmaceutical Corporation offer?
A2: Nymox Pharmaceutical Corporation offers two diagnostic products, NicAlert and TobacAlert, as well as a lead drug candidate for benign prostatic hyperplasia (BPH) called Fexapotide Triflutate (FT).
Q3: In which industry is Nymox Pharmaceutical Corporation primarily involved?
A3: Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies.
Q4: What is the company's focus regarding its lead drug candidate Fexapotide Triflutate (FT)?
A4: The Company's lead drug candidate FT has completed Phase 3 development in more than 70 clinical centers in the United States, involving over 1700 patients during the entire clinical development program. It is also being developed for early-stage, non-aggressive prostate cancer.
Q5: What is the significance of Fexapotide Triflutate (FT) in treating benign prostatic hyperplasia (BPH)?
A5: FT has demonstrated important long-term clinical benefits in men receiving FT, including significant delay in disease progression compared to controls. It offers long-term symptom relief in BPH in excess of currently available oral medications and with no side-effects.
Q6: Where is Nymox Pharmaceutical Corporation headquartered?
A6: The Company is headquartered in Nassau, Bahamas, but it is currently relocating its headquarters from the Bahamas to Switzerland.
Q7: What is the company's stock symbol on NASDAQ National Market?
A7: Nymox Pharmaceutical Corporation's stock is traded on NASDAQ National Market under the symbol NYMX.
Q8: Who is the founder, CEO, and President of Nymox Pharmaceutical Corporation?
A8: Dr. Paul Averback is the founder, CEO, and President of Nymox Pharmaceutical Corporation. He has extensive experience in healthcare and holds a Diploma of the American Board of Pathology with special competence in Neuropathology.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
